Mometasone
drug drugOn this page
Summary
Mometasone (CHEMBL1201404) is an approved small-molecule anti-inflammatory drug targeting NR3C1; indicated across 6 conditions including seasonal allergic rhinitis and allergic rhinitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Targets: 1 (NR3C1)
- Indications: 6 conditions
- Clinical trials: 27
- Chemistry: 427.4 Da · C22H28Cl2O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201404 |
| Name | Mometasone |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 441335 |
| ChEBI | CHEBI:6970 |
| Molecular formula | C22H28Cl2O4 |
| Molecular weight | 427.4 |
| InChIKey | QLIIKPVHVRXHRI-CXSFZGCWSA-N |
SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C
IUPAC name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Pharmacological roles (ChEBI): anti-inflammatory drug, dermatologic drug, vasoconstrictor agent, anti-allergic agent.
Also known as: Mometasone, mometasone, MOMETASONE
Patent coverage: 6,525 distinct patent families (24,288 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | Agonist | 0.9% | P04150 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bile salt export pump.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ABCB11 | 5.03 | IC50 | 9300 | nM | CHEMBL_ACT_18051971 |
Target pathways
Aggregated over 1 target gene(s): NR3C1.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 1 | NR3C1 |
| Nuclear Receptor transcription pathway | 1 | NR3C1 |
| SUMOylation of intracellular receptors | 1 | NR3C1 |
| PTK6 Expression | 1 | NR3C1 |
| Regulation of RUNX2 expression and activity | 1 | NR3C1 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 1 | NR3C1 |
| Potential therapeutics for SARS | 1 | NR3C1 |
| Regulation of NPAS4 gene transcription | 1 | NR3C1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| regulation of gluconeogenesis | 1 |
| chromatin organization | 1 |
| regulation of DNA-templated transcription | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| apoptotic process | 1 |
| chromosome segregation | 1 |
| signal transduction | 1 |
| glucocorticoid metabolic process | 1 |
| response to wounding | 1 |
| gene expression | 1 |
| microglia differentiation | 1 |
| adrenal gland development | 1 |
| nuclear receptor-mediated steroid hormone signaling pathway | 1 |
| regulation of glucocorticoid biosynthetic process | 1 |
Indications & clinical
Indications
6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| seasonal allergic rhinitis | 3 | MONDO:0005324 | EFO:0003956 |
| allergic rhinitis | 3 | MONDO:0011786 | EFO:0005854 |
| otitis media with effusion | 3 | MONDO:0005892 | EFO:0007415 |
| perennial allergic rhinitis | 3 | MONDO:0024332 | EFO:1001417 |
| sickle cell disease | 2 | MONDO:0011382 | MONDO:0011382 |
| sinusitis | 1 | MONDO:0005961 | EFO:0007486 |
Clinical trials
Total trials: 27.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 9 |
| PHASE3 | 7 |
| PHASE2 | 5 |
| PHASE1 | 3 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05626621 | PHASE4 | RECRUITING | Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis |
| NCT00070707 | PHASE4 | COMPLETED | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) |
| NCT00361439 | PHASE4 | TERMINATED | Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis |
| NCT00461812 | PHASE4 | TERMINATED | A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma |
| NCT00763529 | PHASE4 | COMPLETED | Elocon vs Fluticasone in Localized Psoriasis (P03197) |
| NCT00783237 | PHASE4 | COMPLETED | Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431) |
| NCT01676415 | PHASE4 | TERMINATED | Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) |
| NCT03011632 | PHASE4 | COMPLETED | Response of the Airway in Sinusitis and Asthma |
| NCT03590912 | PHASE4 | COMPLETED | Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion |
| NCT00562159 | PHASE3 | COMPLETED | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) |
| NCT00783224 | PHASE3 | COMPLETED | A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512) |
| NCT01401465 | PHASE3 | COMPLETED | Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray |
| NCT02066298 | PHASE3 | COMPLETED | Steroids In Eosinophil Negative Asthma |
| NCT02541760 | PHASE3 | COMPLETED | Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children |
| NCT03449836 | PHASE3 | UNKNOWN | Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children |
| NCT05311475 | PHASE3 | COMPLETED | Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis |
| NCT00557440 | PHASE2 | COMPLETED | Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma |
| NCT00666679 | PHASE2 | COMPLETED | Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) |
| NCT00941798 | PHASE2 | COMPLETED | Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma |
| NCT02318303 | PHASE2 | COMPLETED | To Study GSP 301 in Patients With Seasonal Allergic Rhinitis |
| NCT03758950 | PHASE2 | COMPLETED | Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2 |
| NCT01061333 | PHASE1 | COMPLETED | Early Airway Response to Allergen in Asthmatics (MK-0000-176) |
| NCT02154334 | PHASE1 | COMPLETED | Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine |
| NCT05887843 | PHASE1 | TERMINATED | Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis |
| NCT00576069 | Not specified | RECRUITING | Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma |
| NCT06436534 | Not specified | RECRUITING | Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis |
| NCT01210170 | Not specified | COMPLETED | Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
174 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| FULVESTRANT | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| PODOFILOX | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| ACENOCOUMAROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ALCLOMETASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| APREPITANT | ChEMBL | Phase 4 (approved) | NR3C1 |
| AURANOFIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BECLOMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE PHOSPHORIC ACID | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE VALERATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUDESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUTOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CHLORMADINONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CICLESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOBETASOL PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DANAZOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEFLAZACORT | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXIMETASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXYCORTICOSTERONE PIVALATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXTROTHYROXINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIENESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIFLORASONE DIACETATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DROSPIRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EFAVIRENZ | ChEMBL | Phase 4 (approved) | NR3C1 |
| ENZALUTAMIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EPLERENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ETHINYL ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| EXEMESTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUNISOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINOLONE ACETONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOROMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOXYMESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLURANDRENOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| GLUCAGON | ChEMBL | Phase 4 (approved) | NR3C1 |
| HALCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE BUTYRATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXOCOBALAMIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXYPROGESTERONE CAPROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| IDARUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LASOFOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LOTEPREDNOL ETABONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MASOPROCOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDROXYPROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDRYSONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MESTRANOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE HEMISUCCINATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLTESTOSTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METOPROLOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MIFEPRISTONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MITOTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MOMETASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MONTELUKAST | ChEMBL | Phase 4 (approved) | NR3C1 |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NIMODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NOMEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORETHINDRONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTIMATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| OXYMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PONATINIB | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNICARBATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| QUINESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RACECADOTRIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIBOFLAVIN 5’-PHOSPHATE | ChEMBL | Phase 4 (approved) | NR3C1 |
Related Atlas pages
- Genes: NR3C1
- In clinical trials for: seasonal allergic rhinitis, allergic rhinitis, otitis media with effusion, perennial allergic rhinitis, sickle cell disease
- Drugs: Fulvestrant, Podofilox, Regorafenib, Acenocoumarol, Alclometasone Dipropionate, Amcinonide, Amiodarone, Aprepitant, Auranofin, Bazedoxifene, Beclomethasone Dipropionate, Benzbromarone, Betamethasone, Betamethasone Dipropionate, Betamethasone Phosphoric Acid, Betamethasone Valerate, Budesonide, Butoconazole, Candesartan Cilexetil, Canrenone, Chlormadinone, Ciclesonide, Clobetasol Propionate, Clofazimine, Clotrimazole, Cortisone, Danazol, Daunorubicin, Deflazacort, Desogestrel, Desonide, Desoximetasone, Desoxycorticosterone Pivalate, Dexamethasone, Dextrothyroxine, Dienestrol, Diethylstilbestrol, Diflorasone Diacetate, Doxorubicin, Drospirenone, Econazole, Efavirenz, Enzalutamide, Eplerenone, Estradiol, Estriol, Ethinyl Estradiol, Exemestane, Felodipine, Fludrocortisone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluorometholone, Fluoxymesterone, Flurandrenolide, Fluticasone Furoate, Fluticasone Propionate, Glucagon, Halcinonide, Hydrocortisone, Hydrocortisone Butyrate, Hydroxocobalamin, Hydroxyprogesterone Caproate, Idarubicin, Isoconazole, Isradipine, Ketoconazole, Lasofoxifene, Loteprednol Etabonate, Masoprocol, Medroxyprogesterone, Medrysone, Megestrol, Mestranol, Methylprednisolone, Methylprednisolone Hemisuccinate, Methyltestosterone, Metoprolol, Mifepristone, Mitotane, Mometasone Furoate, Montelukast, Naftopidil, Nimodipine, Nisoldipine, Norethindrone, Norgestimate, Norgestrel, Oxymetholone, Ponatinib, Prednicarbate, Prednisolone, Prednisone, Progesterone, Quinestrol, Racecadotril, RIBOFLAVIN 5’-PHOSPHATE